reserved.
The AMLl/€TO fusion transcript is expressed in virtually all patients with t(8;21)(q22;q22) acute myeloid leukemia (AML). The fusion transcript can be detected by reverse transcription-polymerase chain reaction (RT-PCR) in most of these patients in long-term complete remission (CR) following conventional chemotherapy or autologous bone marrow transplantation (BMT). However, AMLl/€TO expression has not been analyzed in a series of patients following allogeneic BMT. We examined CR bone marrow (BM) samples and, in some cases, blood samples from 10 patients with t(8;21) leukemia who underwent allogeneic BMT in either first or second remission or first or second relapse. A variety of myeloablative regimens were used. Eight patients received non-T-cell depleted BM from matched sibling donors, one patient received a T-cell depleted haploidentical BM, and one patient received a non-T-cell depleted BM from a matched unrelated donor (MUD). Five patients developed acute and/ or chronic graft versus host disease (GVHD). The furthest time points analyzed for the AML VETO transcript in the 10 patients in CR following allogeneic BMT ranged from 7.5 t o 83.0 months. Sufficient RNA was extracted from the most recent BM or BM and blood samples from nine patients t o HE BALANCED translocation between chromosomes 8 and 2 1, t(8; 2 l)(q22; q22), is one of the most frequent recurrent cytogenetic abnormalities in acute myeloid leukemia (AML).' The t(8;21) results in the fusion of the AMLl gene on chromosome 21 to the E T 0 gene on chromosome 8.2-9 The novel chimeric gene (AMLUETO) produces a transcript that is consistently detected by the reverse transcription-polymerase chain reaction (RT-PCR).3.5-7.'0 While its precise role in leukemic transformation remains to be defined,"." the protein product of this chimeric transcript appears to be important for maintaining the leukemic phenotype in leukemic cell lines with the t (8;21) . I3 The presence of the t(8;21) in AML defines a specific morphologic and clinical entity, usually of the M2 type in the French-American-British (FAB) morphology classification scheme. It is associated with a good response to chemotherapy, with both a high remission rate and long-term diseasefree s u r~i v a l . '~"~ In patients treated for t(8;21) AML with either conventional chemotherapy or autologous bone marrow transplantation (ABMT), the AMLI/ETO fusion transcript has usually been detected when assayed by RT-PCR. The transcript has been detected as long as 10 years after attainment of complete morphologic and cytogenetic remisHowever, evaluation for the AMLI/ETO fusion transcript following allogeneic BMT, where the graft-versusleukemia effect may contribute to eradication of the leukemic clone, has only been reported in five patients. In three cases, the fusion transcript was detected by RT-PCR 2, 6, and 18 months after BMT. 19 ." The first case relapsed shortly thereafter and the latter two remain in complete remission (CR). In two cases, the fusion transcript could not be detected 35 and 61 months after allogeneic BMT, and both remain in Thus, the frequency with which the AMLI/ETO * See text for details.
t Death resulting from GVHD *T-cell depleted.
( Table l) . Nine patients were diagnosed with de novo FAB M2 AML, and one patient was diagnosed with refractory anemia with excess blasts in transformation (RAEBT). The median age at diagnosis was 37 years (range, 11 to 56), with an equal distribution of men and women. Patients were transplanted in first remission (CRl, six patients), first relapse (REL1, two patients), second remission (CR2, one patient), or second relapse (REL2, one patient). The donors were HLA-compatible (five or six of six loci) siblings for eight patients, a haploidentical sibling for one patient, and a matched unrelated individual (MUD) for one patient. Transplantation occurred 3 to 40 months after the diagnosis of leukemia. BM or blood was studied from 0.5 to 40 months before BMT and 2 to 83 months after BMT. The median time to last follow-up for all 10 patients was 27 months (range, 7.5 to 87 months). All patients gave informed consent before material was obtained.
Morphologic and cJtugenetic studies o j B M . AML and RAEBT were diagnosed based on standard FAB morphologic and cytochemical criteria.?' Cytogenetic analyses on BM or blood samples were performed using standard techniques following the specifications of the International Standing Committee on Human Cytogenetic Nomenclature (ISCN, 1995) .'" The criteria used to define a cytogenetic clone and descriptions of karyotypes also followed the recommendations of the ISCN.30 The t(8;21)(q22;q22) was identified in all patients before BMT. Each BM used for RT-PCR of the AMLZ/ E T 0 fusion transcript following allogeneic BMT showed CR on routine histologic examination and no evidence of the t(8;21) on cytogenetic analysis. We also analyzed CR BM samples from five patients (UPNs 2, 5, 8, 9, and 10) for the t(8;21) by fluorescence in situ hybridization (FISH) using a probe specific for chromosome 8, as described below. One thousand metaphases from each patient were analyzed without evidence of the t(8;21) by FISH.
Prepurativr regimens and graft-versus-host disease (GVHD). Preparative regimens consisted of (1) Bu/TBI: busulfan (Bu) 8 mg/ kg and total body irradiation (TBI) (12 Gy) in two patients; (2) VP-16/Cy/TBI: etoposide (VP-16) 1,800 mg/mz, cyclophosphamide (Cy) 60 mg/kg/day X 3 days and TB1 (10 Cy) in one patient; (3) BdCy: Bu 16 mgkg and Cy 50 mgkglday X 4 days in one patient; (4) Cy/ TBI: Cy 60 mgkg/day x 2 days and TB1 12 Gy (lungs 10 Gy) in four patients, and (5) Bu/Cy(2): Bu 16 mgkg and Cy 60 mg/kg/day X 2 days in two patients ( Table 1 ). The haploidentical sibling BM was T-cell depleted before infusion into the recipient. Three patients developed acute GVHD; one of these three also developed chronic GVHD. Two patients developed chronic GVHD without acute GVHD.
RT-PCR analysis. Total cellular RNA was extracted by thawing viably frozen bone marrow (BM) or blood mononuclear cells and placing them into RNAzol (Biotecx Laboratories, Houston, TX), following the manufacturer's directions. After quantitation by ultraviolet (UV) spectrophotometry (Spectronic 1201, Milton Roy, Rochester, NY), RNA was diluted to 250 ng/HL, aliquoted into eppendorf tubes at 6 pL/tube, and stored at -70°C until further use. RNA was prepared in a laboratory physically separated from the laboratory where RT-PCR was performed. RT-PCR was performed with rTth DNA polymerase (Perkin Elmer, Foster City, CA) following the manufacturer's instructions, at 60°C for 15 minutes using 0.5 to 2 pg of total RNA. First round PCR was accomplished using all 20 pL from the RT step, with 34 cycles at 94°C (1 minute), 60°C (1 minute) and 72°C (1 minute), followed by one cycle with an elongation step at 94°C (1 minute), 60°C (1 minute) and 72°C (10 minutes). The nested PCR amplification was performed under identical cycling conditions using 1 pL of the first round product and Taq DNA polymerase (Promega, Madison, WI). The sequences of the AMLI/ ET0 primers used were as described by Kusec et al." The nested RT-PCR produced a final 126-bp product that was visualized in a 2% agarose gel. Each aliquot of RNA was also successfully amplified for the p-actin gene product, using commercially available primers (Clontech, Palo Alto, CA) or primers from the Roswell Park Cancer Institute Biopolymer Facility (3':AGGTCCAGACGCAGGATGGC and 5':TGGGTCAGAAGGATTCCTAT). In every experiment, negative RNA and water controls were included throughout RNA extraction, RT and PCR. Strict precautions against contamination were undertaken."
Sensitiviv and spec$city of the RT-PCR. The sensitivity of each RT-PCR was tested by performing a limiting dilution with AMLl/ E T 0 positive Kasumi-l cells (a kind gift from Dr Nanao Kamada)'* in the presence of AMLI/ETO negative K562 cells33 at 10-fold dilutions ranging from undiluted Kasumi-l to one Kasumi-l cell in 10' K562 cells. These experiments showed that the RT-PCR used in this study detected the fusion transcript at a dilution 2 l:lOs in 92% of the experiments. The sensitivity did change between individual use only. 
RESULTS
Amplijkation of the AMLlETOfusion transcript following allogeneic BMT in patients with t (8;21) . In four patients, diagnostic or relapse BM or blood samples obtained before allogeneic BMT were available for amplification by RT-PCR. A 126-bp RT-PCR product consistent with that previously described for the AMLUETO fusion transcript' was detected in all four of these samples (UPNs 1, 3, 6, and 7, Fig 1A) . Following allogeneic BMT, all 18 BM samples examined demonstrated CR on routine histologic examination. CR BM or blood samples from nine of the 10 patients at the furthest time points after allogeneic BMT were positive for the 126-bp RT-PCR product using primers specific for the AMLIETO transcript (Fig 1B) . In the tenth patient (UPN 2), insufficient RNA was extracted from the BM to call it negative by our prospectively established criteria. In each instance, the p-actin transcript was amplified for validation of RNA integrity, and a sensitivity reaction was also performed (Fig IC) . These CR samples were obtained at time points which ranged from 7.5 to 83.0 months after BMT. The median time between the last BM sample analyzed and last follow-up (at which time all nine living patients were without evidence of relapse) is 4 months (range, 3 to 5 months). Unsorted BM samples obtained from each of the three normal donors for UPN 1, UPN 3, and UPN 7 were found to be negative for the fusion transcript by RT-PCR (data not shown).
Sequential BM samples were obtained from three patients following allogeneic BMT, and each was assayed for the AMLUETO fusion transcript by RT-PCR (Fig 2) . UPN 1 died from complications of severe GVHD 7.5 months after an HLA-matched sibling allogeneic BMT, without histologic or cytogenetic evidence of leukemia. BM samples obtained 2, 3, 7, and 7.5 months after BMT were analyzed for the AMLIETO fusion transcript by RT-PCR. The BM at 2 months was negative for the fusion transcript. The BM at 3 months was negative, but a blood sample obtained at the same time was positive. The final two BM samples were both positive. UPN 3 received T-cell depleted BM from an HLA-haploidentical sibling, and developed both acute and chronic GVHD. BM samples obtained 9, 12, and 17 months following BMT contained the AMLUETO fusion transcript. UPN 6 was the only patient in our study who was transplanted with BM from a MUD. He subsequently developed acute GVHD. BM samples obtained at 6, 11, and 18 months following the allogeneic BMT all contained the AMLI/ETO fusion transcript by RT-PCR. A BM sample obtained 25 months after allogeneic BMT was negative for the fusion transcript, but a blood sample obtained at the same time was positive. This was our only patient whose BM converted from the persistence of the fusion transcript following allogeneic BMT to the absence of the fusion transcript.
There were four instances in which BM samples (UPNs 5, 6, 9, and 10) were positive for the AMLI/ETO fusion transcript, and blood samples obtained at the same time were also available for analysis by RT-PCR. In all four imtances, the blood was also positive (Fig 2) . There were two instances in which BM samples (UPNs 1, and 6) were negative for the AMLIIETO fusion transcript, and blood samples obtained at the same time were also available for analysis by RT-PCR. In both instances, the blood was positive. In another patient (UPN S), insufficient BM material was available to conclude that RT-PCR results were negative, but blood obtained at the same time was positive. In samples from two patients, obtained at 7.5 (UPN 1) and 9, 12, and 17 months (UPN 3), respectively, the AMLI/ E T 0 fusion transcript could only be detected following allogeneic BMT when the amount of BM RNA used at the initiation of the RT-PCR was increased from 0.5 pg to 2.0 pg. Only one patient (UPN 2) was without evidence of the AMLl/ETO fusion transcript following allogeneic BMT. In this instance, one BM sample was available, but the total amount of RNA obtained for the RT-PCR was only 1.4 pg (Fig 1B) . RNA could not be isolated from a simultaneous blood sample. Sensitivir?, ofthe RT-PCR for detection ofthe AMLIETO fusion transcript. The issue of RT-PCR sensitivity for the AMLI/ETO fusion transcript and the amount of total RNA used at the initiation of RT-PCR was examined further with the Kasumi-l cell line that contains the fusion transcript, admixed with the K562 cell line that lacks the fusion transcript. Using 0.5 pg of total RNA isolated from a Kasumi-I:K562 dilution of l:lOs, the fusion transcript could be detected in 89% of RT-PCR amplifications ( Table 2) . When a dilution of 1:106 was used, the fusion transcript could be detected in 29% of RT-PCRs. However, if the starting total use only. RNA isolated from a Kasumi-l:K562 dilution of 1:10' was increased from 0.5 pg to 1.0 pg, the fusion transcript could be detected in 78% of RT-PCRs. Using 1 .0 pg of total RNA, the fusion transcript could be detected in 44% of reactions from dilutions of 1:107 as well, but never from dilutions of 1:lO.' Thus, detection of the AMLUETO fusion transcript depends not only on the frequency with which the transcript is found within the starting material, but also on the absolute number of transcript copies. Detection of recipient cells following allogeneic BMT. Blood and BM samples were available to search for donorrecipient chimerism in four patients (UPNs 1, 3, 6 , and 7) who demonstra~ed persistence of the AMLI/ETO fusion transcript following allogeneic BMT. We were unable to obtain 
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evidence of recipient cells in unsorted BM or sorted lymphocyte, granulocyte or monocyte populations of blood using PCR alnplification of unique microsatellites with a 1% sensitivity of detection (not shown). Because CD34 is commonly expressed by the malignant clone in t(8;21) le~kemia,~'-~' we sorted -4 X lo4 CD34' cells from four patient CR BM samples, which also demonstrated the AMLI/ETO fusion transcript by RT-PCR. Evidence of recipient cells, ie, chimerism, was found in two of the four samples (UPNs 1 and 6) by PCR amplification of unique DNA microsatellites. We did not have sufficient material from the sorted cells to assess for the AMLUETO fusion transcript by RT-PCR. As CD34+ cells represented approximately 1% of BM mononuclear cells and our sensitivity is approximately l%,"4 frequency of recipient cells among unsorted BM cells in these two instances could be estimated to be greater than or equal to 1 in 10,000. A representative analysis of patients with (UPN 1) and without (UPN 7) chimerism is shown in Fig 3. Despite evidence for both the AMLUETO fusion transcript and recipient cells following allogeneic BMT in some patients, direct proof that the cell containing the fusion transcript was of recipient origin was lacking. UPN l was positive for the ~M L I / E T O fusion transcript in three of five BM or blood samples tested by RT-PCR following BMT {Fig 2), and showed evidence of chimerism in CD34+ cells obtained at 7 and 7.5 months after BMT, despite absence of histologic or cytogenetic evidence of relapse. UPN l also use only. Four BM samples from 2. 3, 7, and 7.5 months following BMT were analyzed for detection of both recipient markers. The frequency of cells with a Y chromosome in UPN l's four BM samples was 1.3% (Table 3 ). This was significantly higher than in four normal control female BM samples ( 1 3% I' 0%. P < .OOOl). The frequency of +4 among XX cells in UPN l's four CR BM samples was 2.2% ( Table 3) . This was similar to that found in live normal control BM samples (2.2% 1' l.7%, P = .9). The frequency of +4 among XY cells in UPN l's four BM samples was I l . S % (Table 3) . This was significantly higher than in three normal male control BM samples ( 1 l.%-17 1.770, P < .OOOI). To determine if the leukemic clone was primarily in recipient or donor cells of UPN I , we then compared the frequency of +4 in UPN l's XY cells with the frequency of +4 in UPN l's XX cells. When all cells analyzed were considered, there was a significantly higher frequency of +4 in XY cells compared with XX cells ( I 1 5 % 11 2.2%, P = .OOOl). Similarly, for each of UPN l's four BM samples studied, the frequency of +4 among XY cells was significantly higher than the frequency of +4 among XX cells (Table 3) . Thus, for this 
DISCUSSION
In the present report, we provide the largest series to date of leukemia patients with the t(8;21) studied for evidence of the AMLIETO fusion transcript following allogeneic BMT. Before this series, analysis for the AMLUETO fusion transcript was reported in only five cases following allogeneic BMT.'9-2' In three cases, the transcript was detected in BM, and in two other cases the transcript was not detected in blood. The results presented in the current series of 10 patients demonstrate that allogeneic BMT, like conventional chemotherapy and autologous BMT, is usually not sufficient to eliminate expression of AMLI/ETO. This is despite a variety of myeloablative regimens and the fact that most of the patients were transplanted in first remission. The type of allogeneic BMT (ie, matchdmismatched sibling, MUD) also did not appear to have any bearing on the ability to detect the fusion transcript by RT-PCR. Likewise, the transcript was detected in all five patients who had GVHD, where a graft-versus-leukemia effect might also be operat i~e .~~
The dilution experiments performed with the Kasumi-l cell line demonstrated that the absolute quantity of starting material was important for optimizing the sensitivity of AMLUETO detection. The appearance of the transcript following BMT in two patient BM samples only after a minimum of 2 pg of total RNA was amplified supported this finding. In UPN 2, where only a suboptimal amount of total RNA from BM was available for analysis following allogeneic BMT, the fusion transcript might have been detected if optimal amounts of RNA from BM or blood had been available. The observation that blood can contain the AMLI/ETO fusion transcript when it is undetectable in BM was a reproducible finding and consistent with others," but remains to be fully explained. Thus, our data suggest that, in instances where the transcript has been reported as undetectable by RT-PCR following treatment,'8-2'3" the sensitivity of each assay, the amount of starting material, or the source of the starting material (ie, BM versus blood) might have been responsible for the negative results obtained.
Additional assays performed on samples from individual patients support the notion that the cell bearing the AMLU E T 0 fusion transcript was indeed of recipient origin. In three cases with persistence of the fusion transcript following allogeneic BMT, we were unable to detect the AMLUETO fusion transcript in BM obtained directly from the normal donors, despite optimal amplification conditions. However, further enrichment for hematopoietic progenitor cells by cell sorting was not performed. In two of four patients where the transcript was present, we also detected recipient cells using PCR amplification of DNA markers that were independent of the AMLUETO gene. We were able to show that a clonal chromosomal abnormality (ie, +4) associated with the t(8;21) in UPN 1 was detected in cells of recipient origin following allogeneic BMT. Thus, in a limited number of cases, we demonstrated that the presence of the fusion transcript was coincident with detection of recipient cells following allogeneic BMT. Whether the fusion transcript will only be found in recipient cells following allogeneic BMT remains to be determined.
The detection of the AMLUETO fusion transcript following allogeneic BMT is consistent with the ability to detect the BCWABL fusion transcript by RT-PCR following allogeneic BMT for chronic myelogenous leukemia (CML).40 However, patients with the persistence of the BCRLABL transcript after allogeneic BMT for CML have a higher incidence of disease relapse compared with those patients in whom the fusion transcript cannot be dete~ted.~' We demonstrated that the AMLUETO fusion transcript could be detected in nine of nine patients in CR following allogeneic BMT, eight of whom remain alive in continuous CR for 1.6 to 7.0 years. Whether the persistence of the AMLUETO fusion transcript will have any predictive value for relapse following allogeneic BMT remains unresolved. It is likely that quantitative analysis of the t(8;21) fusion transcript on sequential BM samples over several years will be necessary to evaluate the predictive value of this test for relapse.
The data presented in this report suggest that the AMLU E T 0 fusion transcript, by itself, is not capable of inducing malignant transformation in the recipient cells in which it is expressed. This is compatible with experimental evidence that suggests not all leukemic cells harboring a particular molecular defect have the potential for initiating le~kemia.~' Alternatively, donor lymphocytes may maintain a potent suppressive graft-versus-leukemia effect on these recipient cells in vivo. Studies of additional patients evaluated for this fusion transcript following allogeneic BMT may help clarify these clinically relevant issues, as will longer follow-up of the current patients.
